Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
Status:
Recruiting
Trial end date:
2025-05-03
Target enrollment:
Participant gender:
Summary
This phase I trial identifies the best dose, possible benefits, and/or side effects of
duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis
fungoides and Sezary syndrome. Duvelisib may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Giving duvelisib in combination with nivolumab may
work better than giving each of these drugs individually, or treating with the usual approach
in patients with mycosis fungoides and Sezary syndrome.